These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25599028)

  • 1. Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history.
    Nagaich U; Sadhna D
    Int J Pharm Investig; 2015; 5(1):13-9. PubMed ID: 25599028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Medicines Recall Announcements in Saudi Arabia Between 2017 and 2022: An Analysis of Saudi Food and Drug Authority (SFDA) Reports.
    Almutairi M; Algabbani A; Alasiri A; Alhomaidan A; Alqahtani AS
    Ther Innov Regul Sci; 2024 Jul; 58(4):689-695. PubMed ID: 38546962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug and medical device product failures and the stability of the pharmaceutical supply chain.
    Livingston AN; Mattingly TJ
    J Am Pharm Assoc (2003); 2021; 61(1):e119-e122. PubMed ID: 32753251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023.
    Patel R; Vhora A; Jain D; Patel R; Khunt D; Patel R; Dyawanapelly S; Junnuthula V
    Drug Discov Today; 2024 Jun; 29(6):103993. PubMed ID: 38670257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marketing new medical devices.
    LoBuglio RJ
    J Biomater Appl; 1988 Jan; 2(3):425-71. PubMed ID: 3230511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Device recalls and the recalling company's website.
    Hyman WA
    Biomed Instrum Technol; 2011; 45(5):412-5. PubMed ID: 21950445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Categorization and comparisons of drug recalls for manufacturers and compounders.
    Mattingly AN; Mattingly TJ; Nguyen Phan AL; Negash K
    J Am Pharm Assoc (2003); 2022; 62(4):1344-1350. PubMed ID: 35422393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Device Recalls in Orthopedics: Recent Trends and Areas for Improvement.
    Vajapey SP; Li M
    J Arthroplasty; 2020 Aug; 35(8):2259-2266. PubMed ID: 32279947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of FDA drug recalls: A 30-month analysis.
    Hall K; Stewart T; Chang J; Freeman MK
    Am J Health Syst Pharm; 2016 Feb; 73(4):235-40. PubMed ID: 26843501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quality tool for health insurers. A new scale measures "quality orientation" from the customer's point of view.
    Westbrook KW; Pedrick D; Bush V
    J Health Care Mark; 1996; 16(4):30-7. PubMed ID: 10169077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
    Tyrawski J; DeAndrea DC
    J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood product recalls in the United States.
    McCullough J; Riley E; Lindgren B; Pulkrabek S; Hall R; Riley W
    Transfusion; 2014 Sep; 54(9):2276-82. PubMed ID: 24863173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S; Toumi M
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk control drives risk assessment and risk review: A cause and effect model of pharmaceutical drug recall on patient safety.
    Lin ID; Hertig JB
    J Med Access; 2023; 7():27550834231170075. PubMed ID: 37197446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.